Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M204,018Revenue (TTM) $M52,824Net Margin (%)13.5Altman Z-Score--
Enterprise Value $M204,018EPS (TTM) $1.2Operating Margin %26.0Piotroski F-Score--
P/E(ttm)29.0Beneish M-Score--Pre-tax Margin (%)15.8Higher ROA y-yN
Price/Book3.210-y EBITDA Growth Rate %1.3Quick Ratio--Cash flow > EarningsN
Price/Sales3.95-y EBITDA Growth Rate %-4.7Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow23.8y-y EBITDA Growth Rate %-9.9ROA % (ttm)4.2Higher Current Ratio y-yN
Dividend Yield %3.6PEG--ROE % (ttm)11.1Less Shares Outstanding y-yN
Payout Ratio %118Shares Outstanding M6,068ROIC % (ttm)13.8Gross Margin Increase y-yN

Gurus Latest Trades with PFE

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

PFE is held by these investors:

PFE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MADDALUNA ANTHONY JExecutive Vice President 2016-11-09Sell10,000$331.88view
BOURLA ALBERTGroup President 2016-11-04Sell18,390$30.0511.88view
DAMELIO FRANK AExecutive Vice President 2016-05-26Sell100,000$34.49-2.52view
CANGIALOSI LORETTA VSr. Vice President, Controller 2016-05-24Sell86,000$33.97-1.03view
OLSON LAURIE JExecutive Vice President 2016-05-11Sell4,700$33.50.36view
YOUNG JOHN DGroup President 2016-05-10Sell41,700$33.530.27view
DAMELIO FRANK AExecutive Vice President 2016-05-10Sell192,000$33.66-0.12view
READ IAN CChairman & CEO 2016-05-09Sell275,000$33.8-0.53view
SUSMAN SALLYExecutive Vice President 2016-05-09Sell67,884$33.71-0.27view
HILL CHARLES HExecutive Vice President 2016-05-09Sell29,600$33.84-0.65view

Quarterly/Annual Reports about PFE:

    News about PFE:

    Articles On GuruFocus.com
    David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017 
    Procter & Gamble, Pfizer Lead Market Gains Feb 16 2017 
    ANGEL Program Gets National Attention Feb 13 2017 
    US Market Indexes Regain Some of Their Losses on Wednesday Feb 02 2017 
    A Would-Be Dividend Aristocrat With a 3.5% Dividend Yield Jan 24 2017 
    US Market Indexes Lower on Monday Jan 24 2017 
    BioCorRx Receives New Funding for Opioid Drug Jan 22 2017 
    Forester Value Fund Quarterly Update Jan 10 2017 
    Pfizer Inc.: Humira's Biosimilar Meets Primary Endpoint Jan 10 2017 
    Kevin O’Leary’s Top 10 Quality Dividend Stocks Dec 29 2016 

    More From Other Websites
    Roche says Phase II trial supports twin treatment for kidney cancer Feb 18 2017
    Momenta Pharma shares halted as drug application hits speed bump Feb 17 2017
    Trade or fade this week's Dow winners? Feb 17 2017
    AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink Feb 17 2017
    12:01 pm Pfizer and Celltrion Healthcare announce their trial for patients with moderate-to-severe... Feb 17 2017
    New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA®... Feb 17 2017
    New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA®... Feb 17 2017
    Pfizer's Xeljanz Combo Comparable to AbbVie's Humira Feb 17 2017
    Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ Feb 17 2017
    David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017
    Procter & Gamble, Pfizer Lead Market Gains Feb 16 2017
    Here Comes Pfizer's Powerful Breakout Feb 16 2017
    Washington University to collaborate with Pfizer on drug discovery Feb 16 2017
    Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone Feb 16 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)